These results suggest that a fraction of patients treated with chemotherapeutic agents experience resistance to treatment, enhancing the CSC marker CD44 expression in addition to Keap1 mutations and Nrf2 activation in HNSCC and impacting the patients’ overall treatment outcome. The gene discussed is NFE2L2; the disease is head and neck squamous cell carcinoma.